- Home
- PHGE vs BIAF Comparison
PHGE vs BIAF Comparison
Compare PHGE & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHGE | BIAF |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9M | 6.8M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | PHGE | BIAF |
|---|---|---|
| Price | $2.17 | $1.30 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $26.00 | N/A |
| AVG Volume (30 Days) | ★ 136.3K | 78.0K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $6,776,739.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $20.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.50 | $1.18 |
| 52 Week High | $22.06 | $46.53 |
Technical Indicators
Market Signals| Indicator | PHGE | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 49.50 | 35.06 |
| Support Level | $1.50 | $1.18 |
| Resistance Level | $2.85 | $1.74 |
| Average True Range (ATR) | 0.50 | 0.13 |
| MACD | -0.24 | -0.00 |
| Stochastic Oscillator | 15.22 | 14.76 |
Price Performance
Historical ComparisonAbout PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.